Carna Biosciences, Inc. (TYO:4572)
221.00
-6.00 (-2.64%)
Aug 28, 2025, 3:30 PM JST
Carna Biosciences Revenue
Carna Biosciences had revenue of 107.65M JPY in the quarter ending June 30, 2025, a decrease of -20.26%. This brings the company's revenue in the last twelve months to 572.00M, down -60.28% year-over-year. In the year 2024, Carna Biosciences had annual revenue of 636.00M, down -60.86%.
Revenue (ttm)
572.00M
Revenue Growth
-60.28%
P/S Ratio
7.58
Revenue / Employee
9.08M
Employees
63
Market Cap
4.34B
Revenue Chart
Revenue History
Fiscal Year End | Revenue | Change | Growth |
---|---|---|---|
Dec 31, 2024 | 636.00M | -989.00M | -60.86% |
Dec 31, 2023 | 1.63B | 239.00M | 17.24% |
Dec 31, 2022 | 1.39B | -631.00M | -31.28% |
Dec 31, 2021 | 2.02B | 884.00M | 78.02% |
Dec 31, 2020 | 1.13B | -2.07B | -64.67% |
Dec 31, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Dec 31, 2018 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Dec 31, 2017 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Dec 31, 2016 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Dec 31, 2015 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
Company Name | Revenue |
---|---|
Chugai Pharmaceutical | 1,196.21B |
Takeda Pharmaceutical Company | 4,480.25B |
Daiichi Sankyo Company | 1,924.68B |
HOYA Corporation | 876.09B |
Otsuka Holdings | 2,401.70B |
Terumo | 1,037.94B |
Astellas Pharma | 1,944.99B |
Shionogi & | 440.50B |